APA (7th ed.) Citation

CF, C., CS, H., A, B., K, K., E, S., & SK, T. (2021). Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatric blood & cancer, 68(1), e28718. https://doi.org/10.1002/pbc.28718

Chicago Style (17th ed.) Citation

CF, Contreras, Higham CS, Behnert A, Kim K, Stieglitz E, and Tasian SK. "Clinical Utilization of Blinatumomab and Inotuzumab Immunotherapy in Children with Relapsed or Refractory B-acute Lymphoblastic Leukemia." Pediatric Blood & Cancer 68, no. 1 (2021): e28718. https://doi.org/10.1002/pbc.28718.

MLA (9th ed.) Citation

CF, Contreras, et al. "Clinical Utilization of Blinatumomab and Inotuzumab Immunotherapy in Children with Relapsed or Refractory B-acute Lymphoblastic Leukemia." Pediatric Blood & Cancer, vol. 68, no. 1, 2021, p. e28718, https://doi.org/10.1002/pbc.28718.